Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database

• Main Authors: Fabrizio Calapai (Author), Ilaria Ammendolia (Author), Luigi Cardia (Author), Mariaconcetta Currò (Author), Gioacchino Calapai (Author), Emanuela Esposito (Author), Carmen Mannucci (Author)
• Format: Book
• Published: MDPI AG, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Risankizumab is a selective, humanized immunoglobulin G1 (IgG1) monoclonal anti-body directed against interleukin (IL)-23 protein. The therapeutic indication of risankizumab is moderate-to-severe plaque psoriasis and psoriatic arthritis. The safety profile of risankizumab is currently defined by dat...